[
  {
    "ts": "2025-11-17T13:15:00+00:00",
    "headline": "Halda Therapeutics Announces Acquisition by Johnson & Johnson",
    "summary": "Halda to be acquired by Johnson & Johnson for $3.05 billion in cashHalda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical developmentAdditional RIPTAC™ programs in development for major solid tumor types and other serious diseases NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquir",
    "url": "https://finance.yahoo.com/news/halda-therapeutics-announces-acquisition-johnson-131500530.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "041fceb0-05c1-38c7-90b9-a13d792070b1",
      "content": {
        "id": "041fceb0-05c1-38c7-90b9-a13d792070b1",
        "contentType": "STORY",
        "title": "Halda Therapeutics Announces Acquisition by Johnson & Johnson",
        "description": "",
        "summary": "Halda to be acquired by Johnson & Johnson for $3.05 billion in cashHalda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical developmentAdditional RIPTAC™ programs in development for major solid tumor types and other serious diseases NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquir",
        "pubDate": "2025-11-17T13:15:00Z",
        "displayTime": "2025-11-17T13:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/b43e571c1f3ad118bbb5094919ff2cd8",
          "originalWidth": 1296,
          "originalHeight": 540,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/waus2MyEAo3w_Sbp7oz7qA--~B/aD01NDA7dz0xMjk2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b43e571c1f3ad118bbb5094919ff2cd8.cf.webp",
              "width": 1296,
              "height": 540,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fndC1B6ByUU_H1Ezm_zTxg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b43e571c1f3ad118bbb5094919ff2cd8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/halda-therapeutics-announces-acquisition-johnson-131500530.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/halda-therapeutics-announces-acquisition-johnson-131500530.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T13:05:00+00:00",
    "headline": "New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit progression of structural damage at 48 weeks.1 These data were presented at the Inflammatory Skin Disease Summit (ISDS) 2025.",
    "url": "https://finance.yahoo.com/news/long-term-data-reinforces-tremfya-130500576.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "ba98c614-7e8e-3080-960b-2f393b807960",
      "content": {
        "id": "ba98c614-7e8e-3080-960b-2f393b807960",
        "contentType": "STORY",
        "title": "New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis",
        "description": "",
        "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit progression of structural damage at 48 weeks.1 These data were presented at the Inflammatory Skin Disease Summit (ISDS) 2025.",
        "pubDate": "2025-11-17T13:05:00Z",
        "displayTime": "2025-11-17T13:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "(PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qSZrWcbnRRL1JYTreG4GkQ--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k.1EfOOwAn37l11cbOcgUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/long-term-data-reinforces-tremfya-130500576.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/long-term-data-reinforces-tremfya-130500576.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T13:00:00+00:00",
    "headline": "Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics",
    "summary": "NEW BRUNSWICK, N.J., November 17, 2025--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, su",
    "url": "https://finance.yahoo.com/news/johnson-johnson-set-revolutionize-treatment-130000371.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "1e594bc3-f847-3bff-9901-86d77b26d04c",
      "content": {
        "id": "1e594bc3-f847-3bff-9901-86d77b26d04c",
        "contentType": "STORY",
        "title": "Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics",
        "description": "",
        "summary": "NEW BRUNSWICK, N.J., November 17, 2025--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, su",
        "pubDate": "2025-11-17T13:00:00Z",
        "displayTime": "2025-11-17T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a02e119d55f341dd41019c8f770f02bf",
          "originalWidth": 2404,
          "originalHeight": 224,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/z_H7VMKoap63QcmeM596Rg--~B/aD0yMjQ7dz0yNDA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a02e119d55f341dd41019c8f770f02bf.cf.webp",
              "width": 2404,
              "height": 224,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Zey1eflDjshudIkpCcEMOA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a02e119d55f341dd41019c8f770f02bf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-set-revolutionize-treatment-130000371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-set-revolutionize-treatment-130000371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T12:08:00+00:00",
    "headline": "Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ",
    "summary": "Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.",
    "url": "https://finance.yahoo.com/news/growth-stability-2025-investment-face-120800614.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1b09830f-7ee8-3a00-ad9b-ea6142a35236",
      "content": {
        "id": "1b09830f-7ee8-3a00-ad9b-ea6142a35236",
        "contentType": "STORY",
        "title": "Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ",
        "description": "",
        "summary": "Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.",
        "pubDate": "2025-11-17T12:08:00Z",
        "displayTime": "2025-11-17T12:08:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZemfjVvYBRw3W8.nEBguuA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wNN8n2_YU3n6CER2COkU_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/growth-stability-2025-investment-face-120800614.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/growth-stability-2025-investment-face-120800614.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T14:39:44+00:00",
    "headline": "Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment",
    "summary": "Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.",
    "url": "https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "c8ae5711-9ede-37cc-a6d8-8dd58be67929",
      "content": {
        "id": "c8ae5711-9ede-37cc-a6d8-8dd58be67929",
        "contentType": "STORY",
        "title": "Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment",
        "description": "",
        "summary": "Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.",
        "pubDate": "2025-11-17T14:39:44Z",
        "displayTime": "2025-11-17T14:39:44Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/c8ae5711-9ede-37cc-a6d8-8dd58be67929/johnson-johnson-inks-a.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/d47003b69a5bd930672a446b220fd7c8",
          "originalWidth": 1012,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N8_T59Ega2m9fWYxF8q0BA--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/d47003b69a5bd930672a446b220fd7c8.cf.webp",
              "width": 1012,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EpSVohaMNWkiha7A6oNYxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/d47003b69a5bd930672a446b220fd7c8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T13:29:00+00:00",
    "headline": "Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion",
    "summary": "Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant’s oncology pipeline.",
    "url": "https://www.wsj.com/business/deals/johnson-johnson-to-buy-halda-therapeutics-for-3-05-billion-2e460ca1?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "92b35f80-2d1d-3941-ac55-55637a057b36",
      "content": {
        "id": "92b35f80-2d1d-3941-ac55-55637a057b36",
        "contentType": "STORY",
        "title": "Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion",
        "description": "",
        "summary": "Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant’s oncology pipeline.",
        "pubDate": "2025-11-17T13:29:00Z",
        "displayTime": "2025-11-17T13:29:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/92b35f80-2d1d-3941-ac55-55637a057b36/johnson-johnson-to-buy.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/2f8b6e618a945599aa72e9a3268bdd92",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1qQrP.RewpAXj_76eB9zFA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/2f8b6e618a945599aa72e9a3268bdd92.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dbm.0DvikO4OGHBUC8Q.kA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/2f8b6e618a945599aa72e9a3268bdd92.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/deals/johnson-johnson-to-buy-halda-therapeutics-for-3-05-billion-2e460ca1?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]